Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention

There's a good reason why Bausch Health shares are experiencing yet another pullback. A recent clinical trial setback points to further trouble ahead.

The Motley Fool • Feb 4, 2026

BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down

Bausch Health shares slide after late-stage RED-C trials for rifaximin SSD fail, derailing plans to expand Xifaxan's cirrhosis-related use.

Zacks Investment Research • Jan 27, 2026

Down 17.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Bausch (BHC)

Bausch (BHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Jan 26, 2026

Bausch Health's brain dysfunction treatment fails late-stage trial

Bausch Health said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of a late-stage trial.

Reuters • Jan 23, 2026

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

LAVAL, QC, Jan. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy (HE). While safe and well-tolerated, both clinical trials did not meet the primary endpoint.

PRNewsWire • Jan 23, 2026

Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026

LAVAL, QC, Jan. 21, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m.

PRNewsWire • Jan 21, 2026

Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

LAVAL, QC, Jan. 5, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Thomas J. Appio, Chief Executive Officer, will participate at the 44th Annual J.P.

PRNewsWire • Jan 5, 2026

2 Strong Mid-Cap Growth Stocks Dan Loeb Bought in Q3

Dan Loeb of Third Point is a brilliant investor worth watching closely whenever the 13F filings roll in.

24/7 Wall Street • Dec 29, 2025

Bausch Health Announces Final Results and Expiration of Exchange Offers

LAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") and its subsidiary 1261229 B.C. Ltd. (the "Issuer" and, together with the Company, the "Offerors") today announced the final results and expiration of their previously announced offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the "4.875% Notes") and 11.00% Senior Secured Notes due 2028 (the "11.00% Notes" and together with the 4.875% Notes, the "Existing Senior Secured Notes") for up to $1.6 billion aggregate principal amount of the Issuer's 10.00% Senior Secured Notes due 2032 (the "New Notes" and, such offers, the "Offers") , in each case, pursuant to the terms described in a confidential exchange offer memorandum dated November 24, 2025 (the "Exchange Offer Memorandum").

Accesswire • Dec 23, 2025